Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Net Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed Net Margin for 12 consecutive years, with 161.83% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 62179.0% to 161.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 310.28% through Dec 2025, up 249505.0% year-over-year, with the annual reading at 310.25% for FY2025, 249508.0% up from the prior year.
  • Net Margin for Q4 2025 was 161.83% at ImmunityBio, up from 209.83% in the prior quarter.
  • The five-year high for Net Margin was 161.83% in Q4 2025, with the low at 735700.0% in Q1 2022.
  • Average Net Margin over 5 years is 124845.14%, with a median of 45142.08% recorded in 2021.
  • The sharpest move saw Net Margin tumbled -67780000bps in 2022, then skyrocketed 70331583bps in 2023.
  • Over 5 years, Net Margin stood at 23475.13% in 2021, then crashed by -532bps to 148391.78% in 2022, then fell by -13bps to 167923.74% in 2023, then skyrocketed by 100bps to 783.62% in 2024, then skyrocketed by 79bps to 161.83% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 161.83%, 209.83%, and 350.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.